The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is one of the common diseases of the respiratory system. As the disease recurs, damage to the airways and lung tissue gradually worsens, leading to a progressive decline in lung function, affecting the patient's workforce and quality of life, and causing a huge social and economic burden. Diabetes is a common comorbidity of COPD and patients with COPD are at increased risk of developing diabetes, while hyperglycemia can also reduce lung function and contribute to the progression and poor prognosis of COPD. Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a new type of hypoglycemic agent that has been shown to regulate blood glucose levels, reduce inflammatory responses and oxidative stress, and regulate lipid metabolism, among other effects. GLP-1RAs may benefit COPD patients by acting directly on the lung from mechanisms such as reducing the inflammatory response, improving oxidative stress, regulating protease/anti-protease imbalance, improving airway mucus homeostasis, and reducing airway remodeling. This study provides a review of the potential role of GLP-1RAs in COPD and offers new ideas for the and treatment of COPD.

Automated summary

Chronic obstructive pulmonary disease (COPD) is a common respiratory disease that causes progressive lung function decline and affects patients' quality of life. COPD patients are at increased risk of developing diabetes, and high blood glucose levels can worsen COPD progression. Glucagon-like peptide-1 receptor agonist (GLP-1RA), a new type of hypoglycemic agent, has potential benefits for COPD patients by reducing inflammation, oxidative stress, and airway remodeling. This study reviews the potential role of GLP-1RAs in COPD and proposes new ideas for COPD treatment.